Metastatic Medullary Thyroid Cancer, Somatostatin Analogues and Markers
作者： Fabio Pomerri , Marco Boscaro , Gino Marioni , Pier Franco Conte , Ambrogio Fassina
DOI:
关键词:
摘要: Background: Medullary Thyroid Carcinomas (MTC) are rare tumors that occur either sporadically or in a familiar form. It comprises 5-10% of all thyroid cancers. Except for some new drugs tyrosine kinase inhibitors family effective metastatic disease, multiple conventional chemotherapeutic regimens have been used without significant success and treatment with somatostatin analogues is still discussed. Patients methods: We report our experience alternating Octreotide Lanreotide MTC. In the period June 2011-May 2012 seven patients medullary cancer were treated. evaluated clinical biochemical response according to CEA, Calcitonin, Chromogranin A, NSE levels after six courses alternated therapy. Results: The was well tolerated, however, clear evidence clinical/biochemistry/radiological efficacy has not
ecronicon.com 参考文章(18)
A. Maladaki, K. Pazaitou-Panayiotou, Ch. Koussis, A. Drimonitis, I. Vainas, A. Kaprara, A. Chrisoulidou, I. Iakovou, M. Boudina, Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. Journal of Experimental & Clinical Cancer Research. ,vol. 23, pp. 549- 559 ,(2004)
S. Grozinsky-Glasberg, D. J. Gross, New drugs in the therapy of neuroendocrine tumors. Journal of Endocrinological Investigation. ,vol. 35, pp. 930- 936 ,(2012) , 10.3275/8651
Maria C Zatelli, Federico Tagliati, John E Taylor, Roberta Rossi, Michael D Culler, Ettore C degli Uberti, None, Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 2161- 2169 ,(2001) , 10.1210/JCEM.86.5.7489
Furio Pacini, Rossella Elisei, Stefano Anelli, Fulvio Basolo, Arianna Cola, Aldo Pinchera, Somatostatin in medullary thyroid cancer. In vitro and in vivo studies Cancer. ,vol. 63, pp. 1189- 1195 ,(1989) , 10.1002/1097-0142(19890315)63:6<1189::AID-CNCR2820630625>3.0.CO;2-J
J. J. Díez, P. Iglesias, Somatostatin analogs in the treatment of medullary thyroid carcinoma Journal of Endocrinological Investigation. ,vol. 25, pp. 773- 778 ,(2002) , 10.1007/BF03345511
Ph. Rougier, C. Calmettes, A. Laplanche, J. P. Travagli, M. Lefevre, C. Parmentier, G. Milhaud, M. Tubiana, The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer. ,vol. 51, pp. 855- 862 ,(1983) , 10.1002/1097-0142(19830301)51:5<855::AID-CNCR2820510519>3.0.CO;2-J
Philippe Ruszniewski, Sofia Ish-Shalom, Machteld Wymenga, Dermot O’Toole, Rudolf Arnold, Paola Tomassetti, Nigel Bax, Martyn Caplin, Barbro Eriksson, Benjamin Glaser, Michel Ducreux, Catherine Lombard-Bohas, Wouter W. de Herder, Gianfranco Delle Fave, Nick Reed, Jean François Seitz, Eric van Cutsem, Ashley Grossman, Philippe Rougier, Wolfgang Schmidt, Bertram Wiedenmann, Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide Neuroendocrinology. ,vol. 80, pp. 244- 251 ,(2004) , 10.1159/000082875
G Pellegriti, S Leboulleux, E Baudin, N Bellon, C Scollo, J P Travagli, M Schlumberger, Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging British Journal of Cancer. ,vol. 88, pp. 1537- 1542 ,(2003) , 10.1038/SJ.BJC.6600930
Irvin M. Modlin, Igor Latich, Mark Kidd, Michelle Zikusoka, Geeta Eick, Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology. ,vol. 4, pp. 526- 547 ,(2006) , 10.1016/J.CGH.2005.12.008
MOHAMMED F. SAAD, JOSEPH J. GUIDO, NAGUIB A. SAMAAN, Radioactive Iodine in the Treatment of Medullary Carcinoma of the Thyroid The Journal of Clinical Endocrinology and Metabolism. ,vol. 57, pp. 124- 128 ,(1983) , 10.1210/JCEM-57-1-124